| Literature DB >> 34012968 |
Marjan Wouthuyzen-Bakker1, Noam Shohat2,3, Javad Parvizi4, Alex Soriano5.
Abstract
The most preferred treatment for acute periprosthetic joint infection (PJI) is surgical debridement, antibiotics and retention of the implant (DAIR). The reported success of DAIR varies greatly and depends on a complex interplay of several host-related factors, duration of symptoms, the microorganism(s) causing the infection, its susceptibility to antibiotics and many others. Thus, there is a great clinical need to predict failure of the "classical" DAIR procedure so that this surgical option is offered to those most likely to succeed, but also to identify those patients who may benefit from more intensified antibiotic treatment regimens or new and innovative treatment strategies. In this review article, the current recommendations for DAIR will be discussed, a summary of independent risk factors for DAIR failure will be provided and the advantages and limitations of the clinical use of preoperative risk scores in early acute (post-surgical) and late acute (hematogenous) PJIs will be presented. In addition, the potential of implementing machine learning (artificial intelligence) in identifying patients who are at highest risk for failure of DAIR will be addressed. The ultimate goal is to maximally tailor and individualize treatment strategies and to avoid treatment generalization.Entities:
Keywords: debridement; failure; implant retention; machine learning; periprosthetic joint infection; risk score
Year: 2021 PMID: 34012968 PMCID: PMC8126631 DOI: 10.3389/fmed.2021.550095
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Summary of studies depicting independent predictors of DAIR failure in acute PJIs by using multivariate analysis.
| ( | Lora-Tamayo | 2013 | 345 | Immune suppressive drugs | 2.23 | Polymicrobial | 1.77 |
| Serum CRP | 1.22 | Levofloxacin and rifampin | 0.42 | ||||
| Exchange modular components | 0.65 | Vancomycin and rifampin | 0.29 | ||||
| ≥2 debridements | 1.63 | Bacteremia | 1.81 | ||||
| ( | Lora-Tamayo | 2017 | 462 | Rheumatoid arthritis | 2.36 | ||
| Revision prosthesis | 1.37 | ||||||
| Late post-surgical infection | 2.20 | ||||||
| Exchange modular components | 0.60 | ||||||
| ( | Wouthuyzen-Bakker | 2018 | 340 | Male sex | 2.02 | 3.52 | |
| Age > 80 years | 2.60 | ||||||
| COPD | 2.90 | ||||||
| Rheumatoid Arthritis | 5.13 | ||||||
| Fracture | 5.39 | ||||||
| Serum CRP > 150 mg/L | 2.00 | ||||||
| Exchange modular components | 0.35 | ||||||
| ( | Urish | 2017 | 206 | Symptoms > 7 days | 1.68 | 0.59 | |
| ( | Marculescu | 2006 | 99 | Sinus tract | 2.84 | ||
| Symptoms > 8 days | 1.77 | ||||||
| ( | Tornero | 2016 | 143 | Suboptimal antibiotic treatment | 4.92 | ||
| ( | Puhto | 2015 | 113 | Leukocytes > 10 × 109/L | 3.70 | Ineffective empirical antibiotics | 3.20 |
| ( | Vilchez | 2011 | 65 | Late acute PJI | 2.57 | ||
| ≥2 debridements | 4.61 | ||||||
| ( | El Helou | 2010 | 91 | Rifampin in staphylococci PJI | 0.11 | ||
| ( | Martínez-Pastor | 2009 | 47 | Serum CRP > 150 mg/L | 3.57 | No fluoroquinolone in Gram negative | 9.09 |
| ( | Tornero | 2015 | 222 | Chronic renal failure | 5.92 | ||
| Liver cirrhosis | 4.46 | ||||||
| Femoral neck fracture | 4.39 | ||||||
| Revision prosthesis | 4.34 | ||||||
| Cemented prosthesis | 8.71 | ||||||
| Serum CRP > 115 mg/L | 12.3 | ||||||
| ( | Rodriguez-Pardo | 2014 | 174 | Chronic renal failure | 2.56 | Fluoroquinolone in Gram negative | 0.23 |
| ( | Löwik | 2018 | 386 | Male sex | 2.03 | ||
| Left-sided prosthesis | 1.80 | ||||||
| Ischemic heart disease | 1.84 | ||||||
| ( | Tornero | 2014 | 160 | Liver cirrhosis | 12.4 | No fluoroquinolone in Gram negative | 6.5 |
| Serum CRP > 120 mg/L | 1.06 | ||||||
| ( | Bergkvist | 2016 | 35 | Hip fracture | 8.30 | ||
| ( | Byren | 2009 | 112 | Revision prosthesis | 3.10 | 2.9 | |
| Arthroscopic procedure | 4.20 | ||||||
| ( | Vilchez | 2011 | 53 | Serum CRP > 220 mg/L | 20.4 | ||
| ≥2 debridements | 9.80 | ||||||
| ( | Rodriguez | 2010 | 50 | 5.3 | |||
| ( | Letouvet | 2016 | 60 | Number of prior surgeries | 6.30 | 9.4 | |
| Antibiotic treatment <3 months | 20.0 | ||||||
| ( | Soriano | 2006 | 47 | 17.6 |
The presence of bacteremia, the causative microorganism and its susceptibility to antibiotics are sometimes known prior to DAIR, but in most cases not.
Sub-group analysis of patients with a post-surgical PJI due to methicillin-susceptible S. aureus (MSSA).
Sub-group analysis of patients with a post-surgical PJI due to methicillin-resistant S. aureus (MRSA).
No rifampin for Gram positives and no fluoroquinolone for Gram negatives.
CRP, C-reactive protein; COPD, Chronic Obstructive Pulmonary Disease.
Figure 1Preoperative risk scores for DAIR failure. KLIC-score for predicting DAIR failure in early acute (postsurgical) PJI (A) and CRIME80-score for predicting DAIR failure in late acute (hematogenous) PJI (B).